Edwards Lifesciences CorpEW
Edwards Lifesciences Corp Financial Overview 2021–2025
Updated Jul 10, 2026By shedding its legacy Critical Care business for $4.2 billion in FY2024, Edwards Lifesciences transformed into a pure-play structural heart powerhouse. This strategic pivot underscores a bold investment thesis: trading short-term transition noise to capture specialized growth in next-generation transcatheter therapies.
The company maintained a consistent top-line trajectory through this restructuring, with net sales climbing from $5.2 billion in FY2021 to $6.1 billion in FY2025. This expansion is anchored by the Transcatheter Aortic Valve Replacement (TAVR) franchise, which swelled to command 74% of net sales by FY2025. Meanwhile, the emerging Transcatheter Mitral and Tricuspid Therapies (TMTT) segment serves as a secondary growth engine, posting 56.4% growth in FY2025. To defend its clinical moat, Edwards relentlessly funnels capital into innovation, dedicating 18% of net sales to research and development.
Bottom-line performance has been volatile as operations shift. The divestiture artificially spiked diluted earnings to $6.97 per share in FY2024, but subsequent profitability normalized downward, pressured by $325.4 million in litigation and intellectual property expenses. Still, the market awarded the streamlined business a substantial premium. At the close of FY2025, the stock traded at 46.6x earnings with a share price of $85.25, securing a $49.5 billion market capitalization. This high multiple reflects market conviction that aggressive share repurchases and clinical portfolio expansions will ultimately outpace the company's lingering IRS and antitrust hurdles.
Recent Developments (Q4 2025 and Q1 2026)
Edwards Lifesciences sustained top-line momentum in Q1 2026, generating $1.65 billion in net sales for a 16.7% year-over-year increase. The core TAVR franchise grew 14.4%, while TMTT revenues surged 51.9%. Diluted earnings reached $0.66 per share despite slight gross margin compression from foreign currency fluctuations and new manufacturing costs. Following a court injunction blocking its JenaValve acquisition in January 2026, the company quickly pivoted, buying pediatric specialist Autus Valve Technologies for $128.9 million in February 2026. Leadership is also transitioning, with Theodora Mistras appointed Chief Financial Officer effective May 2026.
Bulls highlight accelerating revenue and a $520.1 million repurchase of 4.9 million shares in Q1 2026 as signals of core strength. Bears note persistent IRS transfer pricing disputes and gross margin pressures tied to early-stage therapies. Trading at 45.5x earnings as of May 6, 2026, the stock commands a premium that requires flawless clinical execution.
What to watch: clinical pipeline progress for the acquired Autus pediatric valves; resolution timelines for the ongoing IRS tax litigation.
Rev
$6.07B
FY2025
NI
$1.07B
FY2025
EPS
$1.84
FY2025
OCF
$1.60B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
All EW Financial Metrics(60)
Income Statement
Balance Sheet
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Receivables
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Accrued Liabilities
- Short-Term Debt
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Treasury Stock
- NCI
- Total L&E
- Shares Outstanding
Cash Flow
Recent SEC Filings
Edwards Lifesciences Corp 8-K Report, Executive Changes (May 8, 2026)
Edwards Lifesciences Corporation (EW) held its Annual Meeting of Stockholders on May 7, 2026, where key proposals related to executive compensation and corporate governance were voted upon. The most significant outcome for investors is the approval of the Amended and Restated Long-Term Stock Incentive Compensation Program. This program amendment includes an increase of 7,000,000 shares available for issuance, bringing the total to 341,500,000 shares. This expansion of the equity pool is crucial for future employee and executive compensation, potentially influencing long-term shareholder value through incentive alignment. Additionally, all director nominees were elected, and stockholders approved the advisory proposal on executive compensation and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The overwhelming approval of these proposals suggests continued confidence from shareholders in the company's leadership, compensation strategies, and financial oversight.
Edwards Lifesciences Corp 8-K Report, Executive Changes (May 4, 2026)
Edwards Lifesciences Corporation (EW) has announced a significant leadership change in its finance department, appointing Theodora Mistras as its new Corporate Vice President, Chief Financial Officer, effective May 29, 2026. Ms. Mistras succeeds Scott B. Ullem and brings a strong background in healthcare investment banking from her previous roles at Citigroup and Goldman Sachs, as well as her recent experience as CFO of Viatris, Inc. This appointment signals a potential strategic focus on financial operations and capital allocation under new leadership. Investors should note the comprehensive compensation package, including a substantial base salary, bonus potential, a significant sign-on bonus, and substantial equity awards, which underscores the company's investment in securing experienced financial leadership. The new CFO's compensation package includes an annual base salary of $925,000, a target annual bonus of at least 100% of base salary, a $2,013,000 sign-on bonus, and an initial restricted stock unit (RSU) grant valued at $8,000,000. Future annual equity awards are also planned, with a $4,500,000 grant date value for fiscal year 2026. This structure indicates a strong emphasis on aligning Ms. Mistras's incentives with the company's long-term performance and shareholder value. The company has also provided severance protections and relocation assistance, demonstrating a commitment to supporting its new executive through the transition.
Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 23, 2026)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on April 23, 2026, primarily to disclose its financial results for the first quarter of 2026 via an attached press release. While the 8-K itself doesn't provide granular details, it signals that investors can now access the company's performance metrics for the initial quarter of the year. This includes key financial data such as revenue, earnings per share, and potentially other operational highlights relevant to their cardiovascular and critical care devices business. Investors should carefully review the furnished press release (Exhibit 99.1) for a comprehensive understanding of EW's Q1 2026 performance. This will offer insights into the company's growth trajectory, profitability, and any forward-looking guidance or commentary provided by management. The filing indicates that the company met its reporting obligations for the period, allowing the market to assess its progress against expectations and industry trends.
Edwards Lifesciences Corp 8-K Report, Financial Results (Feb 10, 2026)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on February 10, 2026, to announce its financial results for the fourth quarter of 2025. While the 8-K itself is brief and primarily serves to incorporate the details from a furnished press release (Exhibit 99.1), the core information pertains to the company's performance in the latest reported quarter. Investors should review the accompanying press release for specific figures on revenue, profitability, and any forward-looking guidance provided by the company.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Jan 12, 2026)
Edwards Lifesciences Corporation (EW) announced on January 11, 2026, that its proposed acquisition of JenaValve Technology, Inc. has been blocked by a preliminary injunction granted by the U.S. District Court for the District of Columbia at the request of the U.S. Federal Trade Commission (FTC). Consequently, the transaction will not proceed as planned. This development is a significant setback for Edwards Lifesciences' strategic growth initiatives and integration plans that hinged on the acquisition of JenaValve. Investors should focus on the implications of this failed acquisition, including potential impacts on future revenue streams, market positioning, and the company's capital allocation strategy. While the financial terms of the deal and any termination fees are not detailed in this 8-K, this event signifies a need for management to reassess its inorganic growth strategy and potentially seek alternative avenues for market expansion or product portfolio enhancement. The company's stock performance may be influenced by market reaction to this news and any subsequent management commentary.
View all 8-K filings →